134-LB: Real-World Impact of Intermittently Scanned Continuous Glucose Monitoring on Hemoglobin A1c in People with Type 2 Diabetes in Canada That Use Basal Insulin—A Prospective Chart Review
Bibliographic record
Abstract
The change in HbA1c after initiating FreeStyle Libre or FreeStyle Libre 2 Flash Glucose Monitoring System (FSL and FSL2) in adults with type 2 diabetes (T2D) in a real-world setting was evaluated over a 3-6 month period. Nine sites in Canada collected medical record data prospectively for adults who had started FSL or FSL2 in the last 3 months and with the following criteria: a basal insulin regimen with or without additional glucose lowering medications, and HbA1c 8.0-12.0%. Preliminary data were analysed from 79/138 medical records (n=138; 6 records ineligible, 53 no follow up, ineligible HbA1c or had stopped FSL or FSL2). Participants had the following baseline characteristics (mean±SD): HbA1c 8.9%±0.8, age 67.3±11.5 years (57% ≥65 years), BMI 30.1±6.2 (n=65), insulin use duration 5.3±3.9 years, and 54% were males. The most commonly used non-insulin glucose lowering medications included metformin (87.3%), sodium-glucose co-transporter-2 (SGLT2) inhibitors (62.0%) and sulphonylureas (46.8%). By the end of the study (3-6 months after the index date), mean HbA1c was reduced by 0.6%±1.1 to 8.3%±1.0 (p<0.0001). Observed changes in antihyperglycemic medications from baseline included increased use of GLP-1 agonists from 44.3% to 51.9% and decreased use of DPP4i from 24.1% to 16.5%. This prospective chart review study found that initiating intermittently scanned continuous glucose monitoring in individuals with T2D treated with basal insulin plus other glucose lowering medications was associated with significantly improved HbA1c over a 3-6 month period. Disclosure A. Abitbol: Advisory Panel; Abbott Diabetes, Lilly Diabetes, Dexcom, Inc., Novo Nordisk Canada Inc., Janssen Pharmaceuticals, Inc., Research Support; Abbott Diabetes, Lilly Diabetes, Zucara Therapeutics, Novo Nordisk Canada Inc., Moderna, Inc., Senseonics, Speaker's Bureau; Boehringer Ingelheim (Canada) Ltd., Lilly Diabetes, Amgen Canada, Dexcom, Inc., Novo Nordisk Canada Inc., HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Sanofi. A. B. Jain: Advisory Panel; Abbott, Amgen Canada, Dexcom, Inc., AstraZeneca, Novo Nordisk, Bayer Inc., Insulet Corporation, Takeda Canada, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Research Support; Abbott, Amgen Canada, Novo Nordisk, Speaker's Bureau; Abbott, Amgen Canada, Dexcom, Inc., AstraZeneca, Novo Nordisk, Bausch Health, Canada, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Pfizer Inc. M. Tsoukas: Speaker's Bureau; Novo Nordisk Canada Inc., Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Scientific Affairs, LLC, AstraZeneca, Sanofi. J. Sigalas: None. B. P. Galm: Advisory Panel; Abbott, Boehringer Ingelheim (Canada) Ltd., Novo Nordisk Canada Inc., Pfizer Inc., Research Support; Abbott, Speaker's Bureau; Abbott, Dexcom, Inc., Pfizer Inc. J. Lee: Advisory Panel; Amgen Canada, Research Support; Novo Nordisk, Lilly, Abbott, Speaker's Bureau; Amgen Canada, Canadian Collaborative Research Network, AstraZeneca, Pfizer Inc. K. S. Qureshy: Advisory Panel; Novo Nordisk, Other Relationship; Novo Nordisk, Novo Nordisk, Research Support; Abbott Diagnostics, Novo Nordisk, Speaker's Bureau; AstraZeneca. C. Collins: None. V. C. Woo: Advisory Panel; Abbott, Speaker's Bureau; Dexcom, Inc. Funding Abbott Diabetes Care
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.011 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.003 | 0.008 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".